Monique J. Roobol
YOU?
Author Swipe
View article: Treatment Trajectories in Metastatic Hormone-sensitive Prostate Cancer: A PIONEER+ Big Data Analysis
Treatment Trajectories in Metastatic Hormone-sensitive Prostate Cancer: A PIONEER+ Big Data Analysis Open
This is the largest RWD study of systemic mHSPC treatment. Despite evidence, ADT monotherapy remains the most used first-line therapy. Increased use ADT + ARPI is associated with better persistence and improved outcomes in the real-world s…
View article: Antibiotic Prophylaxis Is Not Required Before MRI-Guided Transperineal Prostate Biopsy
Antibiotic Prophylaxis Is Not Required Before MRI-Guided Transperineal Prostate Biopsy Open
Post-TPBx infections without ABP were rare, occurring in less than 1.0% of cases, even among patients with diabetes or an indwelling catheter. Our results suggest that ABP may be safely omitted in patients undergoing TPBx for prostate canc…
View article: Is it time for Canada to revisit its approach to prostate cancer screening?
Is it time for Canada to revisit its approach to prostate cancer screening? Open
Prostate cancer is the third leading cause of cancer death among Canadian men. Despite advances in the last decade mitigating overdiagnosis and overtreatment, Canadian guidelines have recommended against routine prostate-specific antigen (…
View article: Key Determinants Influencing Treatment Decision-Making for and Adherence to Active Surveillance for Prostate Cancer: A Systematic Review
Key Determinants Influencing Treatment Decision-Making for and Adherence to Active Surveillance for Prostate Cancer: A Systematic Review Open
Background/Objectives: Men choosing active surveillance (AS) for low- and intermediate risk prostate cancer (PCa) must weigh its harms and benefits against those of active treatment (AT). To understand factors influencing treatment decisio…
View article: Corrigendum to “AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium”. [Lung Cancer 205 (2025) 108610]
Corrigendum to “AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium”. [Lung Cancer 205 (2025) 108610] Open
View article: AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium
AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium Open
We identified and critically appraised 21 European lung cancer guidelines published between 2009 and 2025. Key recommendations for improvement include inclusion of diverse specialities and patient representatives in guideline development a…
View article: Informing prostate cancer screening policy makers in the European Union: lessons from cancer screening governance and policymaking
Informing prostate cancer screening policy makers in the European Union: lessons from cancer screening governance and policymaking Open
Prostate cancer (PCa) poses a significant global health threat, with high incidence and mortality rates. In 2022, the Council of the European Union (EU) updated its screening recommendations, prioritizing PCa screening. This signals a cruc…
View article: Reasons for Discontinuation of Active Surveillance in Men with Grade Group 1 and Grade Group 2 Prostate Cancer in the PRIAS Study
Reasons for Discontinuation of Active Surveillance in Men with Grade Group 1 and Grade Group 2 Prostate Cancer in the PRIAS Study Open
View article: Long‐term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment
Long‐term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment Open
Objectives To present the long‐term outcomes of men with Grade Group (GG) 1 prostate cancer (PCa), included in the Prostate Cancer Research International Active Surveillance (PRIAS) study, and to assess the effect of the inclusion of magne…
View article: Targeted Prostate Biopsies Overestimate International Society of Urological Pathology Grade Group, Particularly in Smaller Tumors
Targeted Prostate Biopsies Overestimate International Society of Urological Pathology Grade Group, Particularly in Smaller Tumors Open
In this report, we examined risk factors that could explain why some patients have higher pathological grading at prostate biopsy than on the whole prostate specimen after surgical removal. We found that patients with prostate biopsies tha…
View article: A Personalized, Risk-Based Approach to Active Surveillance for Prostate Cancer with Takeaways from Broader Oncology Practices: A Mixed Methods Review
A Personalized, Risk-Based Approach to Active Surveillance for Prostate Cancer with Takeaways from Broader Oncology Practices: A Mixed Methods Review Open
Background/Objectives: To summarize the current state of knowledge regarding personalized, risk-based approaches in active surveillance (AS) for prostate cancer (PCa) and to explore the lessons learned from AS practices in other types of c…
View article: Monitoring of prostate cancer screening in the European Union: development of key performance indicators through the PRAISE-U project
Monitoring of prostate cancer screening in the European Union: development of key performance indicators through the PRAISE-U project Open
This project has received funding from the EU4Health program under grant agreement 101101217, co-funded by the European Union.
View article: Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance
Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance Open
Importance Active surveillance (AS) for patients with prostate cancer (PC) often includes fixed repeat prostate biopsies that do not account for the varying risk of reclassification to significant disease. Given the invasive nature and pot…
View article: Navigating choices: understanding the decision‐making journey of patients with localised kidney cancer
Navigating choices: understanding the decision‐making journey of patients with localised kidney cancer Open
Objective To explore patients’ experience of decision making regarding treatment of localised kidney cancer. Methods A total of 21 patients with localised kidney cancer, across three countries, participated in either four focus groups or s…
View article: PSA testing in primary care: is it time to change our practice?
PSA testing in primary care: is it time to change our practice? Open
GPs/FDs play an important role in counselling healthy men eligible to consider PSA testing. However, clear guidance, training and support is required for them to assume this role.
View article: An Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER Consortium
An Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER Consortium Open
In this study, we combined several data sources that reported urinary, bowel, and sexual dysfunction, global health status, and quality of life. We identified eight data sources and show that sexual function is the most affected domain aft…
View article: Impact of Additional Active Treatment for Prostate Cancer on Health-related Quality of Life of Men: Results from the EUPROMS 2.0 1-year Follow-up Survey
Impact of Additional Active Treatment for Prostate Cancer on Health-related Quality of Life of Men: Results from the EUPROMS 2.0 1-year Follow-up Survey Open
The follow-up data on quality of life collected by Europa Uomo can be used to inform future prostate cancer (PCa) patients about the impact of undergoing (multiple) PCa treatment(s).
View article: Assessing the Cause of Death for Men with Prostate Cancer Using Official Mortality Statistics or a Dedicated Cause of Death Committee: Results from 30-year ERSPC Rotterdam Data
Assessing the Cause of Death for Men with Prostate Cancer Using Official Mortality Statistics or a Dedicated Cause of Death Committee: Results from 30-year ERSPC Rotterdam Data Open
We compared the classification of prostate cancer death between a dedicated trial committee and official statistics in the Netherlands. We found that official statistics are an accurate representation in determining the cause of death.
View article: AGREE II Quality Assessment of National and International Clinical Practice Guidelines on Prostate Cancer Management by the OPTIMA Consortium
AGREE II Quality Assessment of National and International Clinical Practice Guidelines on Prostate Cancer Management by the OPTIMA Consortium Open
The OPTIMA project used the Appraisal of Guidelines for Research & Evaluation II (AGREE II) tool to evaluate the quality of 16 commonly used national and international clinical practice guidelines for prostate cancer. While some of these i…
View article: Risk-stratified Approach to Implementing Population-based Prostate Cancer Screening in Five Pilot Sites in the European Union: A Protocol for the PRAISE-U Project
Risk-stratified Approach to Implementing Population-based Prostate Cancer Screening in Five Pilot Sites in the European Union: A Protocol for the PRAISE-U Project Open
View article: Prostate Cancer Early Detection in the European Union and UK
Prostate Cancer Early Detection in the European Union and UK Open
This review of 26 reviews covers various aspects of prostate cancer screening such as invitation, decision-making, screening tests, harms, and benefits. This review provides insights into existing evidence, highlighting the areas of consen…
View article: Centralized prostatectomy with intraoperative NeuroSAFE margin assessment improves surgical margin control
Centralized prostatectomy with intraoperative NeuroSAFE margin assessment improves surgical margin control Open
Aims To investigate the surgical margin status in patients with prostate cancer who underwent robot‐assisted radical prostatectomy (RARP) with intraoperative neurovascular structure‐adjacent frozen‐section analysis (NeuroSAFE) and evaluate…
View article: Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry Open
Active surveillance (AS) has evolved into a widely applied treatment strategy for many men with prostate cancer around the world. In this report, we show the long-term safety of following AS for men with low- and intermediate-risk prostate…
View article: Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey
Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey Open
In 2022, the European Commission updated its recommendation on cancer screening, inviting the Member States (MSs) to explore the feasibility of stepwise implementation of population-based screening for prostate cancer (PCa). In line with t…
View article: Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer Open
Objectives To understand how best to further reduce the inappropriate use of pre‐surgical androgen deprivation therapy (ADT), we investigated the determinants (influences) of ADT prescribing in urologists in two European countries using an…
View article: A 2‐year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort
A 2‐year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort Open
Objectives To prospectively evaluate how the Prostate Health Index (PHI) impacts on clinical decision in a real‐life setting for men with a prostate‐specific antigen (PSA) level between 4 and 10 ng/mL and normal digital rectal examination.…
View article: Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe Open
View article: Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer
Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer Open
Objective To evaluate whether a subgroup of men can be identified that would benefit more from screening than others. Materials and Methods This retrospective cohort study was based on three European Randomised Study of Screening for Prost…
View article: Follow-up on Patients with Initial Negative mpMRI Target and Systematic Biopsy for PI-RADS ≥3 Lesions – An EAU-YAU Study Enhancing Prostate Cancer Detection.
Follow-up on Patients with Initial Negative mpMRI Target and Systematic Biopsy for PI-RADS ≥3 Lesions – An EAU-YAU Study Enhancing Prostate Cancer Detection. Open
Purpose To investigate the detection and predictors of prostate cancer (PCA) and clinically significant prostate cancer (csPCA) in patients with positive multiparametric MRI (mpMRI) followed by a negative MRI – guided target biopsy (TB) an…
View article: Predictive Models for Assessing Patients’ Response to Treatment in Metastatic Prostate Cancer: A Systematic Review
Predictive Models for Assessing Patients’ Response to Treatment in Metastatic Prostate Cancer: A Systematic Review Open
In this review, we evaluate studies that predict which treatments will work best for which metastatic prostate cancer patients. We found that existing studies need further improvement before these can be used by health care professionals.